Aristotle University Of Thessaloniki (AUTH)
Κλινική και ανοσολογική μελέτη της επίδρασης των βιολογικών παραγόντων στη νεανική ιδιοπαθή αρθρίτιδα
Abstract
dc:descriptionThe aim of the study was: a) to evaluate the long-term safety and efficacy of biologic agents in patients with Juvenile Idiopathic Arthritis (JIA) and b) to investigate the impact of anti TNFs on Τ cell activation and proliferation response. The safety and efficacy of infliximab etanercept adalimumab and anakinra were assessed in 69 patients (99 sessions) with JIA aged 2-17 years. The impact of anti TNFs on Τ cell function was studied in 24 JIA patients under conventional therapy (2,5-16 yrs) and 13 JIA patients under anti TNFs (3-20 yrs). The safety analysis included the registration of adverse events (AEs). Efficacy was assessed using the criteria of the American College of Rheumatology (ACR) Pediatric 30, 50, 70, 90 and 100 for disease improvement. The percentage of total Β and Τ cells the Τ cells populations CD3+CD4+, CD3+CD8+ and the activation markers CD69, CD71, CD25 and HLA DR of CD3+ Τ cells were determined using flow cytometry. Lymphocyte proliferation was induced in vitro by mitogens. This method evaluates the lymphocyte activation and proliferation response. Common infections were recorded in 24.2% of sessions serious infections in 3% and serious AEs in 4% of sessions. During infliximab treatment and until the end of 2nd year all patients flared. During etanercept treatment and from the 1st until the 5th year an ACRped 50 was achieved in the 86,4%, 91,9%, 90,1%, 86,7% and 85,7% of sessions respectively. During the first 4 years of adalimumab treatment an ACRped 50 was achieved in the 85,29%, 79,31%, 91,67% και 88,9% of sessions respectively. Remission that maintained for over 2 years was achieved by all 3 patients who received anakinra. While the anti TNFs decreased the percentage of activated CD3+ Τ cells they did not normalize their proliferation response due probably to the immunosenescence occurring in JIA.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Διάφα, Κωνσταντίνα
Subjects
dc:subject × 22- Νεανική ιδιοπαθής αρθρίτιδα (ΝΙΑ)
- Βιολογικοί παράγοντες
- Ασφάλεια
- Αποτελεσματικότητα
- Λειτουργικότητα λεμφοκυττάρων
- Αντι-TNF παράγοντες
- Ανταγωνιστής ιντερλευκίνης-1
- ACRped κριτήρια
- Σύγχρονη θεραπεία
- Juvenile idiopathic arthritis
- Biologic agents
- Safety
- Efficacy
- T cells proliferation response
- Anti-TNF agents
- Interleukin-1 antagonist
- ACR pediatric criteria
- Current therapy
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27025